Praxis Precision Medicines (PRAX) Q1 FY26 earnings call

Praxis Precision Medicines is accelerating its transition to a commercial company, driven by significant progress across four late-stage assets with over $20 billion in peak sales potential. The company is actively preparing for two potential U.S. launches in the next eight months, supported by strong clinical data and a robust financial foundation. Key pipeline catalysts are expected throughout the year, including pivotal readouts and regulatory decisions, as Praxis aims to deliver life-altering treatments for CNS disorders.